|
|
|
|
First Bauxite Enters Into Letter of Intent With Bauxite Corporation of Guyana Inc. to Acquire All of the Share
FIRST BAUXITE CORPORATION ('First Bauxite' or the 'Company') (TSX VENTURE: FBX)(FRANKFURT: FBI)(BERLIN: FBI) is pleased to announce that on February 5th, entered into a Letter of Intent with Bauxite Corporation of Guyana Inc.('BCGI') to acquire all of the...
|
|
|
Abbot Sues Qiagen Over Pact for PCR-Based HPV Detection Methods
Abbott Laboratories last week sued Qiagen in a US court in a dispute over a licensing agreement related to patents covering PCR-based detection of human papillomavirus genotypes.The suit, filed on Feb. 3 in the US District Court for the Northern...
|
|
|
California Court of Appeal Orders Arbitration, Finding Arbitration Agreement Not Unconscionable
An arbitration agreement permitting limited discovery and additional discovery upon a showing of need was not unconscionable, the California Court of Appeal has held, reversing a lower court order denying arbitration.Dotson v. Amgen, Inc., No.
|
|
|
Delcath Signs First Partner Agreement in Asia
NEW YORK, Feb.9 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today the signing of its first research,...
|
|
|
Caleco Pharma Corp. Engages ICF Kursmakler AG as Designated
Caleco Pharma Corp.(OTCBB: CAEH)(FRANKFURT: T3R)(WKN: A0N9Y0) ('Caleco Pharma') (www.calecopharmacorp.com) is pleased to announce that it has entered into a designated sponsorship agreement (the 'Sponsorship Agreement') with ICF Kursmakler AG (...
|
|
|
Westaim and NUCRYST Pharmaceuticals collaborate to form a new company
The Westaim Corporation (Westaim or the Company) (TSX: "WED") announced today that, following the approval of the transaction by the shareholders of NUCRYST Pharmaceuticals Corp.(Nucryst), Westaim's wholly-owned subsidiary, 1499642 Alberta Ltd. (1499642),...
|
|
|
Caleco Pharma Corp. Engages ICF Kursmakler AG as Designated Sponsor on Frankfurt Stock Exchange and BlueWater Advisory Group LLC
BELLINGHAM, WASHINGTON -- (Marketwire) -- 02/09/10 -- Caleco Pharma Corp.(OTCBB: CAEH)(FRANKFURT: T3R)(WKN: A0N9Y0) ("Caleco Pharma") (www.calecopharmacorp.com) is pleased to announce that it has entered into a designated sponsorship agreement (the ...
|
|
|
Caleco Pharma Corp. Engages ICF Kursmakler AG as Designated Sponsor on Frankfurt Stock Exchange and BlueWater Advisory Group LLC as Investor Relations
BELLINGHAM, WASHINGTON--(Marketwire - Feb.9, 2010) - Caleco Pharma Corp. (OTCBB: CAEH.OB)(FRANKFURT:T3R)(WKN:A0N9Y0) ("Caleco Pharma") ( www.calecopharmacorp.com) is pleased to announce that it has entered into a designated sponsorship agreement (the...
|
|
|
Caleco Pharma Corp. Engages ICF Kursmakler AG as Designated Sponsor on Frankfurt Stock Exchange and BlueWater Advisory Group LLC as Investor Relations Consultant
(Marketwire via COMTEX) ----Caleco Pharma Corp.(OTCBB:CAEH)(FRANKFURT:T3R)(WKN:A0N9Y0) ("Caleco Pharma") (www.calecopharmacorp.com) is pleased to announce that it has entered into a designated sponsorship agreement (the "Sponsorship Agreement")...
|
|
|
Caleco Pharma Corp. Engages ICF Kursmakler AG as Designated Sponsor on Frankfurt Stock Exchange and BlueWater
BELLINGHAM, WASHINGTON--(Marketwire - Feb.9, 2010) - Caleco Pharma Corp. (OTCBB:CAEH - News; FRANKFURT:T3R - News; WKN:A0N9Y0) ('Caleco Pharma') (www.calecopharmacorp.com) is pleased to announce that it has entered into a designated sponsorship ...
|
|
|
Caleco Pharma Corp. Engages ICF Kursmakler AG as Designated Sponsor on Frankfurt Stock Exchange and BlueWater Advisory Group LLC ..
Caleco Pharma Corp.Engages ICF Kursmakler AG as Designated Sponsor on Frankfurt Stock Exchange and BlueWater Advisory Group LLC as Investor Relations Consultant Refer to a friend Marketwire 2010 BELLINGHAM, WASHINGTON -- (Marketwire) -- 02/09/10 -- Caleco...
|
|
|
Caleco Pharma Corp. Engages ICF Kursmakler AG as Designated Sponsor on Frankfurt Stock Exchange and BlueWater Advisory Group LLC as Investor Relations Consultant
(Marketwire via COMTEX News Network) -- Caleco Pharma Corp.(OTCBB:CAEH)(FRANKFURT:T3R)(WKN:A0N9Y0) ("Caleco Pharma") (www.calecopharmacorp.com) is pleased to announce that it has entered into a designated sponsorship agreement (the "Sponsorship ...
|
|
|
Caleco Pharma Corp. Engages ICF Kursmakler AG as Designated Sponsor on Frankfurt Stock Exchange and BlueWater
roup LLC as Investor Relations Consultant Caleco Pharma Corp.(OTCBB: CAEH)(FRANKFURT: T3R)(WKN: A0N9Y0) ('Caleco Pharma') (www.calecopharmacorp.com) is pleased to announce that it has entered into a designated sponsorship agreement (the 'Sponsorship ...
|
|
|
Caleco Pharma Corp. Engages ICF Kursmakler AG as Designated Sponsor on Frankfurt Stock Exchange and BlueWater
Email a Friend Latest News Releases Permalink BELLINGHAM, WASHINGTON--(Marketwire - Feb.9, 2010) - Caleco Pharma Corp. (OTCBB:CAEH)(FRANKFURT:T3R)(WKN:A0N9Y0) ('Caleco Pharma') (www.calecopharmacorp.com) is pleased to announce that it has entered into a...
|
|
|
PuraMed BioScience Secures up to $7.5 Million Funding Commitment From Southridge Partners II, Ltd.
(GlobeNewswire via COMTEX) ----PuraMed BioScience (OTCBB:PMBS), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines that treat migraine headaches, insomnia and tension-type headaches...
|
|
|
PuraMed BioScience Secures up to $7.5 Million Funding Commitment From Southridge Partners II, Ltd
SCHOFIELD, Wis., Feb.9, 2010 (GLOBE NEWSWIRE) -- PuraMed BioScience (OTCBB:PMBS - News), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines that treat migraine headaches, insomnia and...
|
|
|
PuraMed BioScience Secures up to $7.5 Million Funding Commitment
SCHOFIELD, Wis., Feb.9, 2010 (GLOBE NEWSWIRE) -- PuraMed BioScience (OTCBB:PMBS), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines that treat migraine headaches, insomnia and...
|
|
|
NUCRYST Announces Completion of Amalgamation
Latest Health News PRINCETON, NJ, Feb.8 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp. ('Nucryst') (TSX:NCS / NASDAQ:NCST) today is pleased to announce the completion of the previously announced amalgamation (the 'Amalgamation') of Nucryst with...
|
|
|
NUCRYST Announces Completion of Amalgamation
PRINCETON, NJ, Feb.8 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp. ('Nucryst') (TSX:NCS / NASDAQ:NCST) today is pleased to announce the completion of the previously announced amalgamation (the 'Amalgamation') of Nucryst with 1499642 Alberta Ltd.
|
|
|
Chi-Fu Trading to market and sell Delcath PHP Systems in Taiwan
Delcath Systems, Inc.( DCTH), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today the signing of its first research, distribution, sales and marketing agreement for its...
|
|
|
More Choice for Canadians Travelling to Morocco
The Honourable Rob Merrifield, Minister of State (Transport), today met with Karim Ghellab, Morocco's Minister of Equipment and Transport, to discuss the recently expanded air transport agreement between the two countries.The ministers had a bilateral...
|
|
|
Nabi Biopharmaceuticals Announces Mailing of Definitive Proxy Statement
ROCKVILLE, Md., Feb.9, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI - News) (the 'Company') announced today that it has commenced mailing its definitive proxy statement to stockholders for approval of the exclusive option and license ...
|
|
|
Nabi Biopharmaceuticals Announces Mailing of Definitive Proxy Statement
(GlobeNewswire via COMTEX) ----Nabi Biopharmaceuticals (Nasdaq:NABI) (the "Company") announced today that it has commenced mailing its definitive proxy statement to stockholders for approval of the exclusive option and license agreement ("the NicVAX ...
|
|
|
Nabi Biopharmaceuticals Announces Mailing of Definitive Proxy Statement
ROCKVILLE, Md., Feb.9, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (the 'Company') announced today that it has commenced mailing its definitive proxy statement to stockholders for approval of the exclusive option and license agreement ('the NicVAX...
|
|
|
Nabi Biopharmaceuticals Announces Mailing of Definitive Proxy
ROCKVILLE, Md., Feb.9, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) (the 'Company') announced today that it has commenced mailing its definitive proxy statement to stockholders for approval of the exclusive option and license agreement...
|
